First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using18F-labeled Active-Site Inhibited Factor VII (18F-ASIS): Potential as Companion Diagnostic
Tissue factor (TF) expression in cancers correlates with poor prognosis. Recently, the first TF-targeted therapy was approved by the U.S. Food and Drug Administration for cervical cancer. To unfold the potential of TF-targeted therapies, correct stratification and selection of patients eligible for treatments may become important for optimization of patient outcomes. TF-targeted PET imaging based on